Combination therapy

Inventors: Jacqueline Gibbons (San Francisco, CA); Joyce Mordenti (San Francisco, CA); Michiel De Vries (Leiden, NL); Walter Krauwinkel (Leiden, NL); Taoufik Ouatas (Bizerte, TN)

Assignees: Medivation Prostate Therapeutics LLC; Astellas Pharma Inc.

A61K31/4166 A61K31/438 A61K31/496 A61K31/515 A61K31/55 A61K45/06 A61P35/00 A61K31/435 A61K2300/00

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,161,628
App. No.: 17/959,350
Granted: Dec 10, 2024
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer.

Claims (6)

1. A method of treating prostate cancer in a patient to whom rifampin is administered, comprising co-administering to the patient a daily dose of 240 mg enzalutamide.

2. The method of claim 1 , wherein the prostate cancer is castration-resistant prostate cancer.

3. The method of claim 1 , wherein the prostate cancer is hormone-sensitive prostate cancer.

4. The method of claim 1 , wherein the prostate cancer is metastatic prostate cancer.

5. The method of claim 4 , wherein the prostate cancer is metastatic castration-resistant prostate cancer.

6. The method of claim 4 , wherein the prostate cancer is metastatic hormone-sensitive prostate cancer.

Assignments (9)

CHANGE OF NAME Recorded Dec 5, 2024

From: MEDIVATION PROSTATE THERAPEUTICS, INC.

To: MEDIVATION PROSTATE THERAPEUTICS LLC

Reel/Frame 069516/0437 →

CHANGE OF ADDRESS Recorded Dec 5, 2024

From: MEDIVATION PROSTATE THERAPEUTICS LLC